We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$2.22B
AUM Growth
+$375M
Cap. Flow
+$293M
Cap. Flow %
13.2%
Top 10 Hldgs %
17.55%
Holding
845
New
119
Increased
485
Reduced
177
Closed
64

Top Buys

Rank Stock Value
1
NOVT icon
Novanta
NOVT
+$18.9M
2
IRBT
iRobot
IRBT
+$18.1M
3
MAXR
Maxar Technologies Inc. Common Stock
MAXR
+$18M
4
OII icon
Oceaneering
OII
+$17M
5
DDD icon
3D Systems Corp
DDD
+$10.3M

Top Sells

Rank Stock Value
1
NOC icon
Northrop Grumman
NOC
+$14.9M
2
FTI icon
TechnipFMC
FTI
+$13.5M
3
ARAY icon
Accuray
ARAY
+$10.8M
4
IMMR icon
Immersion
IMMR
+$8.19M
5
XONE
The ExOne Company
XONE
+$4.9M

Sector Composition

Rank Sector Weight
1 Technology 25.66%
2 Industrials 13.74%
3 Healthcare 10.47%
4 Consumer Discretionary 8.12%
5 Financials 7.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBBY
326
DELISTED
Bed Bath & Beyond Inc
BBBY
$1.35M 0.06%
61,336
+5,521
+10% +$120K
MNST icon
327
Monster Beverage
MNST
$92.1B
$1.34M 0.06%
42,224
+1,666
+4% +$49.9K
GOOG icon
328
Alphabet (Google) Class C
GOOG
$4.36T
$1.33M 0.06%
25,500
+8,920
+54% +$454K
JNJ icon
329
Johnson & Johnson
JNJ
$619B
$1.33M 0.06%
9,528
-663
-7% -$92.3K
CMCSA icon
330
Comcast
CMCSA
$89.3B
$1.31M 0.06%
32,829
+16,686
+103% +$627K
CLLS
331
Cellectis
CLLS
$271M
$1.31M 0.06%
45,009
-6,533
-13% -$178K
FPRX
332
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.31M 0.06%
59,767
+18,994
+47% +$611K
XNCR icon
333
Xencor
XNCR
$1.48B
$1.3M 0.06%
59,426
+3,289
+6% +$71.3K
AZN icon
334
AstraZeneca
AZN
$250B
$1.3M 0.06%
18,753
+1,761
+10% +$119K
CHTR icon
335
Charter Communications
CHTR
$18.8B
$1.3M 0.06%
3,860
-1,128
-23% -$383K
TGT icon
336
Target
TGT
$66.8B
$1.29M 0.06%
19,805
-2,386
-11% -$144K
EA icon
337
Electronic Arts
EA
$1.28M 0.06%
12,191
-624
-5% -$69.4K
BLCM
338
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.26M 0.06%
15,043
+4,078
+37% +$400K
WSO icon
339
Watsco Inc
WSO
$13.2B
$1.26M 0.06%
7,413
+3,270
+79% +$540K
DIS icon
340
Walt Disney
DIS
$182B
$1.26M 0.06%
11,695
+621
+6% +$64K
NEE icon
341
NextEra Energy
NEE
$176B
$1.26M 0.06%
32,224
+4,376
+16% +$169K
MGNX icon
342
MacroGenics
MGNX
$255M
$1.25M 0.06%
65,643
+374
+0.6% +$6.98K
JNCE
343
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.24M 0.06%
97,466
+26,628
+38% +$391K
NVS icon
344
Novartis
NVS
$293B
$1.24M 0.06%
16,496
+417
+3% +$31.5K
DVAX
345
DELISTED
Dynavax Technologies
DVAX
$1.24M 0.06%
66,238
-84,020
-56% -$1.69M
GOOGL icon
346
Alphabet (Google) Class A
GOOGL
$4.38T
$1.23M 0.06%
23,420
-9,540
-29% -$492K
IOVA icon
347
Iovance Biotherapeutics
IOVA
$2.77B
$1.23M 0.06%
153,194
-32,434
-17% -$260K
LUMO
348
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.22M 0.06%
+16,727
New +$1.38M
CTMX icon
349
CytomX Therapeutics
CTMX
$734M
$1.22M 0.05%
57,643
-27,896
-33% -$578K
CLDX icon
350
Celldex Therapeutics
CLDX
$3.26B
$1.21M 0.05%
28,505
-4,496
-14% -$193K
12 13
14
15 16

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q4 2017 Portfolio in Review

As of Q4 2017, Vident Investment Advisory held 845 positions worth $2.22B, up 20% from $1.85B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Vident Investment Advisory deployed $293M of net new capital in Q4 2017, opening 119 new positions and adding to 485 existing holdings. Its largest new stake was Novanta: 388,786 shares worth $19.4M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Northrop Grumman, an estimated $14.9M trimmed.

  • Vident Investment Advisory's largest Q4 2017 buy was Novanta: 388,786 shares worth $19.4M.
  • Vident Investment Advisory added most to iRobot in Q4 2017, an estimated $18.1M increase.
  • Vident Investment Advisory's biggest Q4 2017 reduction was Northrop Grumman, cutting an estimated $14.9M.
  • Vident Investment Advisory fully exited TechnipFMC in Q4 2017, selling an estimated $13.5M.
  • Vident Investment Advisory's ten largest holdings make up 18% of its $2.22B portfolio in Q4 2017.
  • Vident Investment Advisory opened 119 new positions and closed 64 in Q4 2017.
  • Vident Investment Advisory's portfolio value rose 20% quarter-over-quarter to $2.22B.

Based on Vident Investment Advisory's 13F filing for Q4 2017, filed 15 Feb 2018.